Dyno Therapeutics inks new partnership with Roche

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche (ROG: SIX) to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases.

Dyno and Roche previously announced a licensing deal for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno Therapeutics provides Roche further access to the company’s field-leading platform and sequence design technologies enabling in vivo gene delivery.

Under the new accord, Dyno is responsible for the design and discovery of novel AAV capsids with improved functional properties. Roche in turn is responsible for conducting capsid validation studies and further pre-clinical, clinical, and commercialization activities for multiple neurological gene therapy product candidates leveraging novel Dyno capsids. Roche will provide Dyno $50 million upfront, along with additional payments during the research phase of the collaboration, plus potential pre-clinical, clinical, and sales milestone payments totaling over $1 billion, and royalties on net sales of commercial products.